Aptevo Therapeutics Inc. Common Stock (APVO)

FairStock Score: 52/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering this clinical-stage biotech at $1.73 as of 2026-10-13, with a $3.1 million market cap. I see no revenue in the filed periods I was given: fiscal Q2 2026, the quarter ended 2026-06-30, had a net loss of $6.4 million and diluted EPS of -$5.31; fiscal Q1 2026, ended 2026-03-31, lost $6.7 million, or -$6.41 per diluted share. Full-year fiscal 2025 lost $26.0 million, or -$87.27 per diluted share; fiscal 2024 lost $24.1 million; fiscal 2023 lost $17.4 million. The trend is not profitable growth but persistent cash consumption. Trailing free cash flow is -$25.3 million, which is -813.0% of the tiny market cap. That is a burning match, not a moat. The ADAPTIR and ADAPTIR-FLEX platforms and lead candidate mipletamig may have optionality, but competitive advantage is unproven. Financially, FairStock calculations show ROE of -420.34%, ROCE of -111.49%, Piotroski 1/9, and Altman Z-Score -27.11. P/B of 0.41 and a Graham Number of $227.10 give a superficially enormous margin of safety, but for a no-revenue company these are accounting artifacts, not a durable bargain. FairStock labels it TURNAROUND because of a loss in the latest year after earlier profits, yet the filed periods I see show losses throughout. The 52-week range of $1.37 to $29.70 tells the story of destroyed equity. Without revenue, cash flow, or a proven pipeline, this is speculation on science and financing, not a Graham-style investment.

In plain English: Aptevo Therapeutics is a small clinical-stage biotech company trying to develop cancer treatments using antibody platforms. It has no reported revenue and has kept losing money in recent quarters and years, while spending more cash than it brings in. The stock price is very low, but the weak financial picture means the cheap-looking price should not be confused with a safe or strong business.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer